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Dietary carotenoids have been hypothesized to protect against epithelial cancers. The authors analyzed the
associations between intakes of speciﬁc carotenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein þ
zeaxanthin, and lycopene) and risk of colorectal cancer using the primary data from 11 cohort studies carried out in
North America and Europe. Carotenoid intakes were estimated from food frequency questionnaires administered
at baseline in each study. During 6–20 years of follow-up between 1980 and 2003, 7,885 incident cases of
colorectal cancer were diagnosed among 702,647 participants. The authors calculated study-speciﬁc multivariate
relative risks and then combined them using a random-effects model. In general, intakes of speciﬁc carotenoids
were not associated with colorectal cancer risk. The pooled multivariate relative risks of colorectal cancer com-
paring the highest quintile of intake with the lowest ranged from 0.92 for lutein þ zeaxanthin to 1.04 for lycopene;
only for lutein þ zeaxanthin intake was the result borderline statistically signiﬁcant (95% conﬁdence interval: 0.84,
1.00). The associations observed were generally similar across studies, for both sexes, and for colon cancer and
rectal cancer. These pooled data did not suggest that carotenoids play an important role in the etiology of
colorectal cancer.
carotenoids; cohort studies; colonic neoplasms; colorectal neoplasms; diet; meta-analysis; rectal neoplasms
Abbreviations: CI, conﬁdence interval; RR, relative risk.
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Colorectal cancer is one of the most common incident
and fatal malignancies worldwide (1), but up to 80 percent
of cases may be preventable through dietary changes (2).
Many substances in plant foods—for example, fiber, folate,
and carotenoids—have been suggested to have anticarcino-
genic capacity (3), but the epidemiologic evidence does not
clearly support protection against colorectal cancer (4).
Carotenoids are red and yellow fat-soluble pigments found
in many fruits and vegetables. They can be divided into those
with and without vitamin A activity. The major carotenoids
with vitamin A activity in human plasma are alpha-carotene,
beta-carotene, and beta-cryptoxanthin, whereas the major car-
otenoids without vitamin A activity are lycopene and luteinþ
zeaxanthin (5). Carrots contain high amounts of alpha-carotene
and beta-carotene. Beta-cryptoxanthin is found mainly in or-
ange juice, oranges, and tangerines. Tomatoes contain high
amounts of lycopene, whereas broccoli and spinach pro-
vide lutein þ zeaxanthin and their isomers (5–8). Because of
the difficulty involved in separating lutein and zeaxanthin in
laboratory analyses, most food composition databases use a
combined value for lutein þ zeaxanthin intake (6, 8).
In case-control studies, the risks of colon and rectal can-
cer have generally been lower with increasing total carot-
enoid intake (9–12). Of the specific carotenoids evaluated,
beta-carotene has been most extensively examined in epide-
miologic studies, partly because of its abundance and the
availability of food composition data (13). In most (14–17)
but not all (10) case-control studies, higher intakes of beta-
carotene have been associated with a reduced risk of colon
or rectal cancer. However, the results for beta-carotene in-
take have been inconsistent in cohort studies of colorectal
cancer (18–20), in studies of precursor lesions for colorectal
cancer (adenomas) (21–24), and in clinical trials of beta-
carotene supplementation (25, 26). Data on associations
between intakes of other specific carotenoids and colon or
rectal cancer risk also have been conflicting (11, 19, 20,
27–29).
To better understand the relation of specific dietary carot-
enoids (alpha-carotene, beta-carotene, beta-cryptoxanthin,
luteinþ zeaxanthin, and lycopene) to colorectal cancer risk,
we analyzed the primary data from 11 large cohort studies
carried out in North America and Europe. These studies,
taken together, provided a wide range of carotenoid intakes
and a large number of cases, which allowed for separate
analyses by tumor site in the large bowel (proximal colon,
distal colon, and rectum) and in subgroups of the study
population.
MATERIALS AND METHODS
The Pooling Project of Prospective Studies of Diet and
Cancer (The Pooling Project) is a collaborative project in-
volving multiple cohort studies (30). For the carotenoid–
colorectal-cancer analyses, we identified 11 cohort studies
(table 1) (19, 20, 31–38) that met the following predefined
criteria: at least 50 incident colorectal cancer cases; assess-
ment of long-term dietary intake, including intake of the
specific carotenoids; and a validation study of the dietary
questionnaire or of a closely related instrument. The Advent-
ist Health Study (39), the New York University Women’s
Health Study (40), and the Ormonie Dieta nella Eziologia
dei Tumori (ORDET) Study (41), all included in other co-
lorectal cancer analyses within the Pooling Project, were
excluded from these analyses because the investigators did
not assess intakes of the specific carotenoids. Each of the
studies included here had been previously reviewed and
approved by the review board of the institution at which
the study was conducted.
Because the Cancer Prevention Study II Nutrition Cohort,
the Netherlands Cohort Study on Diet and Cancer, and the
New York State Cohort included both women and men, each
of these studies was analyzed as containing two separate
cohorts defined on the basis of sex. To take advantage of
the more extensive dietary assessment completed in 1986,
the cases and person-time accumulated in the Nurses’
Health Study were divided into two groups for analysis
(1980–1986 and 1986–2000); these cohorts are referred to
as Nurses’ Health Study (a) and Nurses’ Health Study (b),
respectively. The Canadian National Breast Screening Study
and the Netherlands Cohort Study on Diet and Cancer were
each analyzed as a case-cohort study (42) because the
investigators in those studies processed questionnaires
for only a random sample of the cohort to represent the
person-time of the cohort and for all participants who were
diagnosed with colorectal cancer during follow-up.
Outcome ascertainment
Colorectal cancer cases were ascertained in each study
using follow-up questionnaires with subsequent medical rec-
ord review (33, 37), linkage with a cancer registry (20, 31,
32, 34, 43), or both (19, 35, 36). In addition, some studies
used linkage with a death registry (19, 20, 31–33, 35, 36,
38, 43).
Dietary assessment
Food consumption was assessed at baseline using a vali-
dated food frequency questionnaire developed for each study
population (44–51). The number of food items on the ques-
tionnaires ranged from 45 for the New York State Cohort (48)
to 276 in the Alpha-Tocopherol, Beta-Carotene Cancer Pre-
vention Study (45). The food data were converted into daily
nutrient intakes according to the software and food compo-
sition database used in each cohort study before they were
sent to the Department of Nutrition at the Harvard School of
Public Health (Boston, Massachusetts). Nutrient data were
energy-adjusted according to the residual method (52) using
predicted intakes of 2,100 kcal/day in men and 1,600 kcal/
day in women. Mean energy intake ranged from 1,802 kcal/
day (Cancer Prevention Study II Nutrition Cohort) to
2,814 kcal/day (Alpha-Tocopherol, Beta-Carotene Cancer
Prevention Study) in men and from 1,279 kcal/day (Breast
Cancer Detection Demonstration Project) to 2,065 kcal/
day (Canadian National Breast Screening Study) in women
(table 1).
In the validation analyses of the included cohort stud-
ies, the investigators generally did not examine specific
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TABLE 1. Characteristics of cohort studies included in a pooled analysis of energy-adjusted dietary carotenoid intake and colorectal cancer, Pooling Project of Prospective
Studies of Diet and Cancer
Study and sex of
subjects (ref. no.)
Follow-up
period
Baseline
cohort
size (no.)
No. of
cases
Mean dietary intake
Energy
(kcal/day)
Alpha-
carotene
(lg/day)
Beta-
carotene
(lg/day)
Beta-
cryptoxanthin
(lg/day)
Lycopene
(lg/day)
Lutein þ
zeaxanthin
(lg/day)
Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study (men) (19) 1985–1999 26,987 321 2,814 (768)* 522 (504) 1,741 (1,254) 25 (30) 620 (573) 1,141 (323)
Breast Cancer Detection
Demonstration Project (women) (35) 1987–1999 41,987 436 1,279 (527) 532 (577) 3,401 (2,999) 98 (95) 1,542 (1,852) 2,752 (3,747)
Canadian National Breast
Screening Study (women) (20) 1980–2000 49,613 612 2,065 (650) 991 (821) 4,633 (2,949) 80 (58) 8,909 (8,998) 3,046 (3,090)
Cancer Prevention Study II Nutrition
Cohort (36)
Women 1992–1999 74,046 479 1,362 (476) 388 (355) 2,658 (1,900) 76 (61) 4,446 (3,135) 1,943 (2,221)
Men 1992–1999 66,071 720 1,802 (616) 503 (463) 3,321 (2,423) 78 (64) 5,479 (3,760) 2,200 (2,481)
Health Professionals Follow-up Study
(men) (33) 1986–2000 47,766 597 1,986 (619) 978 (1,030) 5,159 (3,583) 88 (103) 10,864 (7,871) 3,960 (3,076)
Iowa Women’s Health Study
(women) (31) 1986–2001 34,588 1,010 1,799 (597) 772 (824) 4,526 (3,162) 74 (72) 4,181 (4,257) 2,794 (2,823)
Netherlands Cohort Study on Diet and
Cancer (34)
Women 1986–1993 62,412 501 1,689 (397) 687 (586) 2,901 (1,542) 205 (173) 1,302 (1,890) 2,440 (1,027)
Men 1986–1993 58,279 646 2,162 (501) 679 (528) 2,937 (1,450) 151 (160) 1,043 (1,547) 2,541 (1,116)
New York State Cohort (32)
Women 1980–1987 22,550 296 1,636 (565) 1,147 (854) 6,357 (3,381) 247 (264) 5,702 (4,116) 5,998 (3,792)
Men 1980–1987 30,363 492 2,132 (790) 1,173 (867) 6,393 (3,457) 216 (274) 7,281 (4,750) 6,034 (3,500)
Nurses’ Health Studyy (women) (33)
Nurses’ Health Study (a) 1980–1986 88,651 220 1,569 (500) 724 (840) 4,425 (3,632) 105 (92) 5,257 (5,308) 5,088 (5,291)
Nurses’ Health Study (b) 1986–2000 68,502z 648 1,770 (524) 765 (637) 4,273 (2,403) 62 (62) 9,646 (6,140) 3,531 (2,553)
Swedish Mammography Cohort
(women) (38) 1987–2003 60,950 706 1,585 (445) 743 (753) 2,843 (2,142) 373 (424) 1,102 (1,066) 1,269 (913)
Women’s Health Study (women) (37) 1993–2002 38,384 201 1,728 (533) 786 (761) 4,097 (2,563) 63 (67) 8,511 (5,972) 3,465 (2,707)
Total 702,647 7,885
Women 473,181 (67%) 5,109 (65%)
Men 229,466 (33%) 2,776 (35%)
* Numbers in parentheses, standard deviation.
y The cases and person-time accumulated in the Nurses’ Health Study (33) were divided into two groups for analysis (1980–1986 and 1986–2000); these cohorts are referred to as Nurses’
Health Study (a) and Nurses’ Health Study (b), respectively.
z These participants were also included in Nurses’ Health Study (a) and are not included in the total baseline cohort size.
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carotenoids (44–51). The energy-adjusted and deattenuated
correlations comparing the food frequency questionnaire
with two 1-week dietary records were over 0.60 for total
carotenoid intake in the Health Professionals Follow-up
Study (47) and the New York State Cohort (48). The Pearson
energy-adjusted, deattenuated correlation coefficients be-
tween food frequency questionnaires and reference methods
ranged from 0.30 to 0.58 for beta-carotene (50, 51, 53). The
correlation coefficients exceeded 0.50 for fruits, citrus fruits,
and fruit juices and were between 0.09 and 0.62 for total
vegetables and specific groups of vegetables (45, 49, 51).
Statistical methods
After applying the exclusion criteria used in each study,
we further excluded participants if they had reported loge-
transformed energy intakes beyond three standard devia-
tions from the study-specific loge-transformed mean energy
intake or if they had reported a history of cancer (except
nonmelanoma skin cancer) at baseline.
We analyzed associations with specific carotenoids by
quintiles of intake. For the Canadian National Breast Screen-
ing Study and the Netherlands Cohort Study on Diet and
Cancer, study-specific quintiles were assigned on the basis
of distributions in the subcohort; for the remaining studies,
study-specific quintiles were based on the distributions in
the baseline cohort. In further analyses, we defined catego-
ries using cutpoints based on identical absolute intakes
across studies. Two-sided 95 percent confidence intervals
and p values were calculated. To calculate the p value for
the test for trend across categories of intake, we assigned
participants the median value of their category of intake and
entered this variable as a continuous term in the regression
model.
Each study was analyzed using a Cox proportional hazards
model (54). Person-years of follow-up were calculated from
the date on which the baseline questionnaire was returned to
the date of colorectal cancer diagnosis, the date of death, or
the end of follow-up, whichever came first. In the analyses,
we simultaneously accounted for age, calendar time, and
time since entry into the study by including age at baseline
in years and the year of the baseline questionnaire as strati-
fication variables and by treating follow-up time as the time
scale. Relative risks and their 95 percent confidence inter-
vals were estimated using SAS PROC PHREG (55).
Relative risks were adjusted for age, education, body mass
index (weight (kg)/height (m)2), height, alcohol consumption,
smoking habits, family history of colorectal cancer, physical
activity, use of nonsteroidal antiinflammatory drugs, energy
intake, red meat intake, total milk intake, folate intake from
food, and use of multivitamin supplements (see table 2 for
the categories used). For women, the relative risks were also
adjusted for history of oral contraceptive use and postmeno-
pausal hormone use. We had no missing data for any nutrients.
An indicator variable for missing responses for measured co-
variates within a study was created when needed. For each
covariate, data generally were missing for less than 5 percent
of the participants in each study (30).
We used a random-effects model (56) to combine the
study-specific loge relative risks, which were weighted by
the inverse of their variance. We tested for heterogeneity
among studies using the Q statistic (56, 57) and for variation
in relative risks by sex, smoking status, oral contraceptive
use, postmenopausal hormone use, multivitamin supple-
ment use, meat consumption, and polyunsaturated fatty acid
intake using meta-regression models (58).
We evaluated whether associations differed among sub-
sites of colorectal cancer using a Wald test to test the null
hypothesis of no difference among the loge relative risks
(59, 60). For these analyses, we fitted separate Cox propor-
tional hazards models for each tumor site. Colon cancers
were considered those tumors located in the area from the
cecum through the sigmoid colon. Tumors in the area from
the cecum to the splenic flexure were considered proximal
colon cancers. The remaining tumors in the colon were de-
fined as distal colon cancers. Rectal cancers included tumors
located in the rectum and the rectosigmoid junction. Per-
sons with cancer at multiple sites or with missing data on
cancer site were included in the colorectal cancer analyses
but were excluded from the specific tumor site analyses.
RESULTS
The pooled data included 7,885 incident colorectal cancer
cases (5,109 in women and 2,776 in men) diagnosed among
702,647 participants who were followed for 6–20 years
across studies (table 1). The follow-up rates for these studies
generally exceeded 90 percent. Reported carotenoid intakes
varied across the cohorts (table 1). The New York State Co-
hort had the highest reported intakes, with two exceptions:
Lycopene intake was highest in the Health Professionals
Follow-up Study, and beta-cryptoxanthin intake was highest
in the Swedish Mammography Cohort. The lowest reported
intakes were in the Alpha-Tocopherol, Beta-Carotene Can-
cer Prevention Study, with one exception: Alpha-carotene
intake was lowest in the Cancer Prevention Study II Nutri-
tion Cohort.
In the age-adjusted analyses, the pooled relative risk of
colorectal cancer comparing the highest quintile of intake
with the lowest ranged from 0.89 for lutein þ zeaxanthin to
1.01 for lycopene (table 2). Most of the age-adjusted results
were attenuated after adjustment for confounding factors
related to colorectal cancer risk. In the multivariate analy-
ses, the relative risks for colorectal cancer were less than
unity in each of the four higher luteinþ zeaxanthin quintiles
as compared with the lowest quintile of intake (highest quin-
tile vs. lowest: pooled relative risk (RR) ¼ 0.92, 95 percent
confidence interval (CI): 0.84, 1.00; test for trend: p¼ 0.08).
The study-specific relative risk for the highest quintile of
lutein þ zeaxanthin intake versus the lowest ranged from
0.70 to 1.18 across studies (test for between-studies hetero-
geneity: p ¼ 0.67); a significant inverse association was
found only among women in the Cancer Prevention Study
II Nutrition Cohort (RR ¼ 0.70, 95 percent CI: 0.51, 0.96).
For beta-carotene intake, statistically significant between-
studies heterogeneity was found for quintile 5 (table 2).
The study-specific relative risks ranged from 0.62 to 1.44,
with statistically significant associations being observed
only in the Canadian National Breast Screening Study
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(RR ¼ 0.62, 95 percent CI: 0.46, 0.84) and among men in
the Cancer Prevention Study II Nutrition Cohort (RR ¼
0.77, 95 percent CI: 0.60, 0.98). The p value from the trend
test for between-studies heterogeneity showed results consis-
tent with those observed for the highest quintile for each
carotenoid, with the exception of alpha-carotene, for which
the test for heterogeneity for trend was of borderline sta-
tistical significance.
Because beta-carotene is present primarily in fruits and
vegetables, we examined whether the association between
beta-carotene intake and colorectal cancer risk differed by
the number of fruit and vegetable items on the food fre-
quency questionnaire in each study, but there was no differ-
ence by the number of items (p ¼ 0.78). In further analyses
for lycopene, no association was observed between lycopene
intake and colorectal cancer risk when the models included
only those cohorts (Breast Cancer Detection Demonstra-
tion Project, Cancer Prevention Study II Nutrition Cohort,
Health Professionals Follow-up Study, Iowa Women’s Health
Study, Nurses’ Health Study (b), and Women’s Health Study)
for which tomato-sauce consumption (a major source of bio-
available lycopene in many populations) was included in
the food frequency questionnaire (highest quintile vs. lowest:
pooled RR ¼ 1.08, 95 percent CI: 0.98, 1.20). None of the
associations for the specific carotenoids was modified by
sex in the age-adjusted or multivariate analyses. The re-
sult for beta-carotene was also similar after exclusion of the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
and the Women’s Health Study, which both had beta-
carotene interventions. Further adjustment for either dietary
folate or dietary fiber did not materially change the results
(data not shown).
Results for each carotenoid were not significantly dif-
ferent by period of follow-up. When cases diagnosed
TABLE 2. Pooled relative risk of colorectal cancer by quintile of dietary carotenoid intake, Pooling Project of Prospective Studies of
Diet and Cancer*
Carotenoid
Quintile 2 Quintile 3 Quintile 4 Quintile 5 p value
RRy 95% CIy RR 95% CI RR 95% CI RR 95% CI
Test
for
trend
Test for
between-
studies
heterogeneity
for quintile 5
Test for
between-
studies
heterogeneity
due to sex
for quintile 5
Alpha-carotene
Age-adjusted 1.01 0.93, 1.08 1.05 0.97, 1.12 0.99 0.90, 1.09 0.94 0.87, 1.02 0.13 0.37 0.88
Multivariatez 1.03 0.95, 1.10 1.09 1.01, 1.17 1.03 0.94, 1.14 1.01 0.93, 1.09 0.75 0.55 0.91
Beta-carotene
Age-adjusted 0.97 0.90, 1.04 0.95 0.86, 1.05 0.91 0.80, 1.03 0.90 0.81, 0.99 0.03 0.03 0.60
Multivariatez 0.99 0.92, 1.07 0.99 0.89, 1.11 0.95 0.82, 1.10 0.96 0.85, 1.09 0.39 0.01 0.54
Beta-cryptoxanthin
Age-adjusted 0.96 0.88, 1.04 0.93 0.86, 1.00 0.90 0.83, 0.96 0.93 0.86, 1.01 0.12 0.29 0.65
Multivariatez 0.98 0.90, 1.06 0.96 0.89, 1.04 0.93 0.86, 1.01 0.99 0.91, 1.07 0.51 0.71 0.33
Lycopene
Age-adjusted 1.01 0.94, 1.08 0.93 0.86, 1.01 0.92 0.86, 0.99 1.01 0.94, 1.09 0.65 0.36 0.59
Multivariatez 1.02 0.94, 1.09 0.94 0.87, 1.02 0.94 0.87, 1.02 1.04 0.96, 1.12 0.60 0.83 0.51
Lutein þ zeaxanthin
Age-adjusted 0.90 0.84, 0.97 0.89 0.83, 0.96 0.84 0.78, 0.90 0.89 0.82, 0.95 0.01 0.61 0.64
Multivariatez 0.91 0.85, 0.98 0.91 0.84, 0.98 0.86 0.79, 0.93 0.92 0.84, 1.00 0.08 0.67 0.81
* Quintile 1 was the reference category (RR ¼ 1.00).
yRR, relative risk; CI, conﬁdence interval.
z Adjusted for education (less than high school, completion of high school, or more than high school), body mass index (weight (kg)/height (m)2;
<23, 23–<25, 25–<30, or 30 kg/m2), height (<1.60, 1.60–<1.65, 1.65–<1.70, 1.70–<1.75, or 1.75 m for women and <1.70, 1.70–<1.75,
1.75–<1.80, 1.80–<1.85, or 1.85 m for men), alcohol consumption (0, >0–<5, 5–<15, 15–<30, or 30 g/day), smoking (never smoker, past
smoker (<20, 20–<40, or 40 years’ duration), or current smoker (<25 cigarettes/day and <40 years, <25 cigarettes/day and 40 years, 25
cigarettes/day and <40 years, or 25 cigarettes/day and 40 years)), family history of colorectal cancer (no/yes), degree of physical activity (low,
medium, or high), use of nonsteroidal antiinﬂammatory drugs (no/yes), energy intake (continuous), red meat intake (quartiles), total milk intake
(quartiles), folate intake from food (quintiles), and use of multivitamins (categories: ‘‘no,’’ ‘‘yes, <6 times/week,’’ ‘‘yes, 6 times/week,’’ or ‘‘yes, but
missing dose’’ for the Breast Cancer Detection Demonstration Project (35), the Heath Professionals Follow-up Study (33), the Iowa Women’s
Health Study (31), Nurses’ Health Study (a) and (b) (33), and the Women’s Health Study (37); no/yes for the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study (19), the Cancer Prevention Study II Nutrition Cohort (36), the Netherlands Cohort Study on Diet and Cancer (34), and
the New York State Cohort (32)). For women, relative risks were also adjusted for history of oral contraceptive use (ever/never) and use of
postmenopausal hormone therapy (premenopausal, dubious menopausal status, postmenopausal ever user, postmenopausal never user, or
postmenopausal but missing data on hormone therapy).
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during the first 5 years of follow-up were excluded from the
analyses (3,201 cases excluded), the result for each carot-
enoid was not materially different from the result includ-
ing all cases. For example, in these analyses, the pooled
multivariate relative risk of colorectal cancer for lutein þ
zeaxanthin intake was 0.92 (95 percent CI: 0.82, 1.04;
highest quintile vs. lowest); for cases diagnosed within the
first 5 years after baseline, the pooled multivariate relative
risk for the same comparison was 0.91 (95 percent CI: 0.80,
1.05).
Because of earlier findings that the association between
carotenoid intake and colon cancer risk might vary by age
(27), we also stratified our results by age at case diagnosis:
less than 65 years (n ¼ 2,934 cases; 37 percent) versus 65
years or older (n ¼ 4,951 cases; 63 percent). For alpha-
carotene, beta-cryptoxanthin, lycopene, and lutein þ zea-
xanthin, there was no more than a 10 percent difference in
the relative risks comparing the highest quintile of intake
with the lowest for each age group in comparison with the
overall result shown in table 2. For beta-carotene, the asso-
ciations for the two age groups were significantly different
(p for difference¼ 0.02), although the relative risks for both
age groups were nonsignificant; the pooled multivariate
relative risks (highest quintile vs. lowest) were 1.08 (95 per-
cent CI: 0.91, 1.28; p for between-studies heterogeneity ¼
0.09) among persons younger than age 65 years and 0.90
(95 percent CI, 0.79, 1.02; p for between-studies heteroge-
neity ¼ 0.12) among persons aged 65 years or older. The
Nurses’ Health Study (a) was excluded from the analyses of
participants aged 65 years or older because only one case
was older than 65 years of age at diagnosis.
Results for each carotenoid were not significantly dif-
ferent between users and nonusers of multivitamins (p for
interaction > 0.1). Among nonusers of multivitamin sup-
plements (4,631 cases; 59 percent of the cases), the pooled
multivariate relative risks of colorectal cancer for the highest
quintile compared with the lowest were 1.06 (95 percent CI:
0.95, 1.17) for alpha-carotene, 1.00 (95 percent CI: 0.90, 1.12)
for beta-carotene, 1.03 (95 percent CI: 0.93, 1.14) for beta-
cryptoxanthin, 1.10 (95 percent CI: 1.00, 1.21) for lycopene,
and 0.90 (95 percent CI: 0.80, 1.00) for lutein þ zeaxanthin.
The Canadian National Breast Screening Study and the
Swedish Mammography Cohort were excluded from these
analyses because the investigators did not have data on
multivitamin use. Furthermore, the associations between in-
take of each carotenoid and colorectal cancer risk were not
modified by smoking status (never, past, or current smoker),
oral contraceptive use (ever vs. never), postmenopausal hor-
mone use (never, past, or current use, among postmenopausal
women only), red meat consumption (tertiles), alcohol intake
(<5 g/day, 5–<15 g/day, or15 g/day), and polyunsaturated
fatty acid intake (tertiles; data not shown).
We also categorized participants into deciles to examine
more extreme contrasts in intakes of each carotenoid. For
luteinþ zeaxanthin, no reduction in risk was observed in the
second decile of intake, whereas the risks were below 1 (but
not all statistically significant) in the upper deciles (highest
decile of intake vs. lowest: pooled multivariate RR ¼ 0.93,
95 percent CI: 0.83, 1.04). For lycopene, the association
became slightly more positive among all studies (highest
decile vs. lowest: pooled multivariate RR¼ 1.10, 95 percent
CI: 0.99, 1.22). This result was similar when we restricted
the analysis to those studies in which tomato sauce con-
sumption was included on the food frequency questionnaire.
We further analyzed the intake of lutein þ zeaxanthin
using identical categories defined by absolute intake cut-
points across studies. Compared with lutein þ zeaxanthin
intake of <1,000 lg/day, the pooled multivariate relative
risks of colorectal cancer were 0.96 (95 percent CI: 0.88,
1.03) for lutein þ zeaxanthin intake of 1,000–<2,000 lg/
day, 0.89 (95 percent CI: 0.77, 1.03) for intake of 2,000–
<3,000 lg/day, 0.87 (95 percent CI: 0.74, 1.02) for intake of
3,000–<4,000 lg/day, and 0.87 (95 percent CI: 0.78, 0.98)
for intake of 4,000 lg/day (p for trend < 0.01). A luteinþ
zeaxanthin intake of 2,000 lg is equivalent to the amount in
approximately 100 g of broccoli (8). The Alpha-Tocopherol,
Beta-Carotene Cancer Prevention Study was excluded from
the three upper categories of lutein þ zeaxanthin intake
because fewer than 0.5 percent of the participants had in-
takes in those categories.
We examined associations between specific carotenoid
intakes and colorectal cancer risk separately for cancers of
the colon (number of cases ¼ 5,581), proximal colon (num-
ber of cases ¼ 2,924), distal colon (cases ¼ 2,211), and
rectum (cases ¼ 2,139) (table 3). For each carotenoid, asso-
ciations were not significantly different between colon and
rectal cancers or between proximal and distal colon cancers
(except for alpha-carotene).
DISCUSSION
In this pooled analysis, in general, no association between
intake of specific carotenoids and colorectal cancer risk was
found. However, a high intake of lutein þ zeaxanthin was
nonlinearly associated with a slightly lower risk of colorec-
tal cancer in analyses using either study-specific quintiles or
identical absolute intake cutpoints. The possible inclusion
of undiagnosed early cases of colorectal cancer in our study
is unlikely to have biased our findings, because the results
were quite similar after we excluded cases diagnosed during
the first 5 years of follow-up. For each carotenoid, associa-
tions with colon cancer and rectal cancer were similar.
Carotenoids have been hypothesized to decrease the risk
of gastrointestinal cancer because of their antioxidant prop-
erties, which protect lipid membranes from damage by free
radicals (61). Patients with adenomatous polyps (precursor
lesions of colorectal cancer) have lower concentrations of
specific carotenoids in their colonic mucosa compared with
controls, despite having similar serum concentrations (62).
Colorectal adenomatous tissue also has been shown to have
lower concentrations of specific carotenoids compared with
noninvolved mucosal tissue (63). These findings support the
suggestion that oxidative stress may be higher in the colonic
mucosa of patients with adenomatous polyps. Lutein and
zeaxanthin are more effective than beta-carotene as scav-
engers against oxygen radicals. Beta-carotene, however, re-
sides in the inner part of the cell membrane, whereas lutein
and zeaxanthin, with less hydrophobic structures, react with
free radicals in membranes during the aqueous phase,
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TABLE 3. Pooled multivariate relative risk* of colorectal cancer according to carotenoid intake and tumor subsitey, Pooling Project of Prospective Studies of Diet and Cancerz
Carotenoid and
subsite
Quintile 2 Quintile 3 Quintile 4 Quintile 5 p value
RR§ 95% CI§ RR 95% CI RR 95% CI RR 95% CI
Test
for
trend
Test for
between-
studies
heterogeneity
for quintile 5
Test for common
effects between
colon and
rectal cancer
for quintile 5
Test for common
effects between
proximal and
distal colon cancer
for quintile 5
Alpha-carotene
Colon 1.03 0.94, 1.12 1.06 0.97, 1.16 1.01 0.89, 1.14 0.99 0.89, 1.10 0.52 0.18
Proximal colon 1.08 0.96, 1.22 1.12 0.99, 1.26 1.08 0.93, 1.25 1.09 0.95, 1.25 0.36 0.34
Distal colon 0.94 0.82, 1.08 1.01 0.88, 1.17 0.93 0.77, 1.13 0.86 0.72, 1.03 0.12 0.15
Rectum 1.01 0.87, 1.16 1.16 1.01, 1.33 1.11 0.96, 1.28 1.06 0.91, 1.23 0.70 0.79 0.45 0.04
Beta-carotene
Colon 0.95 0.85, 1.05 0.98 0.86, 1.12 0.90 0.76, 1.05 0.92 0.79, 1.08 0.24 0.001
Proximal colon 0.92 0.82, 1.04 1.02 0.88, 1.18 0.96 0.82, 1.13 1.02 0.85, 1.24 0.56 0.02
Distal colon 0.98 0.82, 1.16 0.96 0.82, 1.11 0.81 0.64, 1.03 0.81 0.66, 0.98 0.02 0.08
Rectum 1.12 0.97, 1.29 1.04 0.90, 1.21 1.14 0.98, 1.33 1.11 0.93, 1.32 0.56 0.26 0.13 0.09
Beta-cryptoxanthin
Colon 0.99 0.90, 1.09 0.98 0.90, 1.07 0.92 0.84, 1.01 0.99 0.90, 1.08 0.59 0.78
Proximal colon 0.98 0.87, 1.10 0.97 0.86, 1.09 0.90 0.80, 1.02 0.95 0.83, 1.08 0.17 0.81
Distal colon 1.02 0.87, 1.20 1.04 0.90, 1.20 0.97 0.81, 1.15 1.02 0.88, 1.19 0.80 0.52
Rectum 0.95 0.79, 1.13 0.94 0.81, 1.08 0.96 0.83, 1.11 1.01 0.87, 1.17 0.88 0.60 0.79 0.44
Lycopene
Colon 1.00 0.92, 1.08 0.91 0.82, 1.01 0.92 0.84, 1.00 1.02 0.93, 1.11 0.74 0.83
Proximal colon 1.00 0.89, 1.13 0.93 0.82, 1.06 0.94 0.83, 1.06 1.04 0.92, 1.18 0.29 0.38
Distal colon 1.02 0.89, 1.18 0.87 0.76, 1.00 0.92 0.80, 1.05 0.99 0.86, 1.14 0.68 1.00
Rectum 1.12 0.98, 1.29 1.08 0.92, 1.25 1.06 0.92, 1.23 1.16 1.00, 1.34 0.50 0.48 0.16 0.60
Lutein þ zeaxanthin
Colon 0.93 0.85, 1.01 0.91 0.83, 0.99 0.87 0.79, 0.95 0.93 0.85, 1.03 0.28 0.63
Proximal colon 0.91 0.79, 1.04 0.92 0.81, 1.03 0.93 0.82, 1.05 0.96 0.84, 1.10 0.69 0.70
Distal colon 0.99 0.87, 1.13 0.92 0.80, 1.06 0.82 0.70, 0.95 0.89 0.76, 1.04 0.09 0.89
Rectum 0.88 0.76, 1.01 0.91 0.79, 1.05 0.85 0.73, 0.98 0.91 0.78, 1.07 0.30 0.99 0.80 0.46
* Adjusted for education (less than high school, completion of high school, or more than high school), body mass index (weight (kg)/height (m)2; <23, 23–<25, 25–<30, or 30 kg/m2),
height (<1.60, 1.60–<1.65, 1.65–<1.70, 1.70–<1.75, or 1.75 m for women and <1.70, 1.70–<1.75, 1.75–<1.80, 1.80–<1.85, or 1.85 m for men), alcohol consumption (0, >0–<5,
5–<15, 15–<30, or 30 g/day), smoking (never smoker, past smoker (<20, 20–<40, or 40 years’ duration), or current smoker (<25 cigarettes/day and <40 years, <25 cigarettes/day and
40 years, 25 cigarettes/day and <40 years, or 25 cigarettes/day and 40 years)), family history of colorectal cancer (no/yes), degree of physical activity (low, medium, or high), use of
nonsteroidal antiinﬂammatory drugs (no/yes), energy intake (continuous), red meat intake (quartiles), total milk intake (quartiles), folate intake from food (quintiles), and use of multivitamins
(categories: ‘‘no,’’ ‘‘yes, <6 times/week,’’ ‘‘yes, 6 times/week,’’ or ‘‘yes, but missing dose’’ for the Breast Cancer Detection Demonstration Project (35), the Heath Professionals Follow-up
Study (33), the Iowa Women’s Health Study (31), Nurses’ Health Study (a) and (b) (33), and the Women’s Health Study (37); no/yes for the Alpha-Tocopherol, Beta-Carotene Cancer
Prevention Study (19), the Cancer Prevention Study II Nutrition Cohort (36), the Netherlands Cohort Study on Diet and Cancer (34), and the New York State Cohort (32)). For women, relative
risks were also adjusted for history of oral contraceptive use (ever/never) and use of postmenopausal hormone therapy (premenopausal, dubious menopausal status, postmenopausal ever
user, postmenopausal never user, or postmenopausal but missing data on hormone therapy).
y Colon cancers were considered those tumors located in the area from the cecum through the sigmoid colon. Tumors in the area from the cecum to the splenic ﬂexure were considered
proximal colon cancers, and the remaining tumors in the colon were deﬁned as distal colon cancers. Rectal cancers included tumors located in the rectum and the rectosigmoid junction.
Numbers of cases by subsite: proximal colon, n ¼ 2,924; distal colon, n ¼ 2,211; rectum, n ¼ 2,139.
z Quintile 1 was the reference category (RR ¼ 1.00).
§ RR, relative risk; CI, conﬁdence interval.
2
5
2
M
a¨
n
n
is
to¨
e
t
a
l.
A
m
J
E
p
id
e
m
io
l
2
0
0
7
;1
6
5
:2
4
6
–
2
5
5
thereby increasing membrane integrity (64). Carotenoids
may also regulate cell growth and cell proliferation, modu-
late gene expression, and affect the immune response (21,
65, 66).
Several observational studies have previously examined
the association between carotenoid intake and colorectal
cancer risk. In a cohort of residents of a retirement com-
munity (a study that did not meet our inclusion criteria) in
which there were 97 colorectal cancer cases in women
and 105 cases in men, intake of beta-carotene was not as-
sociated with colorectal cancer risk; associations with other
carotenoids were not examined (18). Inverse associations
have been reported most consistently for lutein þ zeaxan-
thin, alpha-carotene, and beta-carotene in case-control stud-
ies (11, 14–17, 27–29), especially among studies with a low
average level of carotenoid intake (27, 29). Our results also
suggest that colorectal cancer risk was elevated only with
very low lutein þ zeaxanthin intakes.
A recent case-control study from Canada found that the
inverse association between lutein þ zeaxanthin intake and
colon cancer risk was limited to women with high intakes of
long-chain polyunsaturated fatty acids (66). In our study,
polyunsaturated fatty acid intake did not modify the associ-
ation between lutein þ zeaxanthin intake and colorectal
cancer risk. The Canadian study also showed that associa-
tions for some of the carotenoids varied by smoking status;
the risk of colon cancer was lower with higher beta-carotene
intake in never smokers and with higher lycopene intake in
smokers. In a US multicenter prevention trial, smoking and
alcohol consumption modified the effect of beta-carotene
supplementation on the risk of colorectal adenoma recur-
rence (24). Our result for each carotenoid was not modified
by smoking or alcohol drinking. In contrast to our results
showing no difference in the association for lutein þ zea-
xanthin by age at diagnosis, a large US case-control study
found the strongest inverse association between lutein intake
and colon cancer risk among persons younger than age 65
years (27). The authors of that study speculated that younger
participants could recall their diets more accurately than
older participants. However, a recent validation study com-
paring a food frequency questionnaire and a 3-day diet rec-
ord found that men older than 50 years reported total
carotenoid intake more accurately than did younger men,
whereas women reported carotenoid intakes with similar
accuracy in all age groups (67). Furthermore, cancers diag-
nosed at younger ages are suggested to have a stronger ge-
netic basis, while cancers diagnosed at older ages are
believed to be more related to environmental influences (68).
In studies using prospectively collected blood samples, no
association has been observed between blood levels of beta-
carotene (19, 69) and colorectal cancer risk. Additionally,
large controlled trials have not found reduced risks of colo-
rectal cancer among study subjects assigned to beta-carotene
supplementation (25, 26, 70), which is in agreement with our
current results.
A strength of our study was the large compilation of data
from multiple cohort studies, such that we could examine
associations between carotenoid intakes and colorectal can-
cer risk with greater statistical power than was possible in
any of the individual studies included in the analysis (30).
These pooled data facilitated analyses by different age
groups, smoking groups, and tumor sites of the large bowel. Be-
cause the analyses were limited to prospective cohort stud-
ies, recall and selection biases were minimized. However,
because the Pooling Project was initiated retrospectively,
each of these cohort studies was planned independently, and
numerous characteristics—such as the age range of the par-
ticipants, the covariates measured, and the food frequency
questionnaire used—differed across studies. However, in our
pooled analyses, we standardized the categorizations of the
dietary variables and covariates across studies to minimize
potential sources of heterogeneity. In addition, for each ca-
rotenoid, except beta-carotene, there was no statistically sig-
nificant heterogeneity between studies, suggesting that the
differences in relative risk among the cohorts were compat-
ible with random variation.
A limitation of our study concerns the assessment of in-
takes of specific carotenoids. We only had a single measure
of carotenoid intake at baseline and were not able to in-
vestigate carotenoid intakes at younger ages or changes in
carotenoid intake during follow-up. There also may have
been variation in the carotenoid values in the different nu-
trient databases used across the studies. Furthermore, be-
cause fruits and vegetables contain many compounds that
may decrease cancer risk (71), an association with a specific
carotenoid may merely be a marker of one or more other
compounds present in fruits and vegetables—for example,
folate, isothiocyanate, and chlorophyll in green vegetables
(72–74). Although we adjusted for intake of folate and for
multivitamin use, it is possible that other substances in fruits
and vegetables are primarily responsible for the associations
observed for lutein þ zeaxanthin, beta-carotene, and lyco-
pene. The association between lutein þ zeaxanthin intake
and colorectal cancer risk remained similar after additional
adjustment for total intake of vegetables, the main sources
of lutein þ zeaxanthin (data not shown). We also could not
correct our results for measurement error, because caroten-
oid intakes were not evaluated in most of the validation
analyses carried out for these cohort studies. Furthermore,
we were not able to account for colorectal cancer screening
in our analyses, because those data were not available in
most of our studies. It may be that persons who are screened
for colorectal cancer are more likely to adhere to a healthier
diet and have higher carotenoid intakes than persons who
are not screened for colorectal cancer.
In summary, these pooled multivariate data do not support
an important association between intakes of specific carot-
enoids (alpha-carotene, beta-carotene, beta-cryptoxanthin,
lutein þ zeaxanthin, and lycopene) and colorectal cancer
risk.
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